Stryker
Pairs orthopaedic implants with Mako robotics, surgical equipment and vascular devices.
Something off on this page? Send us feedback.
Profile
Sells orthopaedic implants, Mako robotic systems, surgical instruments, endoscopy equipment, hospital-care technology, neurocranial devices and vascular tools across Orthopaedics and MedSurg and Neurotechnology. Most revenue comes from U.S. hospitals and clinicians, with implants paired to the instruments, navigation and robotics used in procedures.
Runs Orthopaedics and MedSurg and Neurotechnology businesses spanning implants, procedure technology and hospital equipment. Orthopaedics covers knees, hips, trauma and extremities; Ortho Tech groups Mako robotics and enabling technologies with power tools and cutting accessories.
MedSurg and Neurotechnology includes surgical instruments and navigation, endoscopy, patient handling, emergency and intensive-care products, clinical communications and virtual-care software, neurocranial devices, and vascular tools for stroke and venous thromboembolism. Inari broadened clot-removal offerings, while the spinal-implant business was sold.
Pairs implants with the instruments, planning software and robotic systems used in procedures, while most products are marketed directly to hospitals and clinicians. The United States supplies most sales, with additional business across Europe, the Middle East, Africa and Asia-Pacific. Product launches depend on regulatory review, while reimbursement and healthcare cost-containment measures shape adoption and pricing.
Company facts
Categories
Key statistics
Year to date −5.0% · Average volume (30d) 2.3M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | Wolfe Research | Downgrade | Buy | Peer Perform | ||
| Jul 31, 2026 | RBC Capital | Reiterate | Outperform | $435 | $420 | |
| Jul 31, 2026 | Raymond James | Target | $418 | $370 | ||
| Jul 31, 2026 | BTIG | Reiterate | Buy | $371 | $358 | |
| Jul 31, 2026 | Piper Sandler | Reiterate | Overweight | $420 | $390 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026Q2 FY26 | $3.49 | $3.69 | +5.7% | $6.58B | $6.59B | +0.1% | −6.42% |
| Apr 30, 2026Q1 FY26 | $2.98 | $2.60 | −12.8% | $6.34B | $6.02B | −5.0% | −6.47% |
| Jan 29, 2026Q4 FY25 | $4.40 | $4.47 | +1.6% | $7.12B | $7.17B | +0.7% | +4.31% |
| Oct 30, 2025Q3 FY25 | $3.13 | $3.19 | +1.9% | $6.04B | $6.06B | +0.2% | −3.45% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $5.87B | $6.02B | $6.06B | $7.17B | $6.02B | $6.59B | |
| Gross profit | $3.68B | $3.75B | $3.85B | $4.68B | $3.81B | $4.50B | |
| Operating income | $1.18B | $1.36B | $1.14B | $1.96B | $936.0M | $1.66B | |
| Net income | $654.0M | $884.0M | $859.0M | $849.0M | $745.0M | $1.28B | |
| Diluted EPS | $1.69 | $2.29 | $2.22 | $2.20 | $1.93 | $3.30 | |
| Gross margin | 62.7% | 62.3% | 63.6% | 65.2% | 63.3% | 68.3% | |
| Operating margin | 20.1% | 22.6% | 18.7% | 27.3% | 15.5% | 25.2% |
Fiscal years (4-quarter sums)FY21 $17.11B · FY22 $18.45B · FY23 $20.50B · FY24 $22.60B · FY25 $25.12B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $3.48B · Total debt $14.94B · Total assets $47.93B · Shareholders' equity $23.99B
Dividends
Raised for 16 straight years — most recently to $0.88 from $0.84 in Dec 2025. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jun 30, 2026 | Jun 30 | Jul 31 | $0.88 | |
| Mar 31, 2026 | Mar 31 | Apr 30 | $0.88 | |
| Dec 31, 2025 | Dec 31 | Jan 30 | $0.88 | raised from $0.84 |
| Sep 30, 2025 | Sep 30 | Oct 31 | $0.84 | |
| Jun 30, 2025 | Jun 30 | Jul 31 | $0.84 | |
| Mar 31, 2025 | Mar 31 | Apr 30 | $0.84 | |
| Dec 31, 2024 | Dec 31 | Jan 31 | $0.84 | raised from $0.80 |
| Sep 30, 2024 | Sep 30 | Oct 31 | $0.80 |
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 383.36M · Float 347.76M · 90.7% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 27.41M | 7.15% | 13F | Aug 7, 2026 |
| Vanguard Capital Management LLC | 22.54M | 5.88% | 13F | Aug 13, 2026 |
| JPMorgan Chase & Co | 17.26M | 4.50% | 13F | Aug 12, 2026 |
| State Street Corp | 15.53M | 4.05% | 13F | Aug 7, 2026 |
| Greenleaf Trust | 15.23M | 3.97% | 13F | Jul 21, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 21, 2026 | Dylan Bram Crotty | officer: Group President | −441 | $328.61 |
| Aug 19, 2026 | Ronda E. Stryker | director | −50,000 | $340.10 |
| Aug 18, 2026 | Ronda E. Stryker | director | −300,000 | $335.90 |
| Aug 18, 2026 | Debra King | officer: See Remarks | −826 | $336.30 |
| May 28, 2026 | Robert S. Fletcher | officer: VP, Chief Legal Officer | −4,544 | $306.87 |
Peers
- Johnson & Johnson
Broadest rival: ortho implants, Velys robotics, instruments, neurovascular.
- Zimmer Biomet
Pure-play ortho implants and ROSA robotics — head-to-head in knees and hips.
- Medtronic
Broad rival: instruments, spine robotics, neurovascular, and patient monitoring.
- Smith & Nephew (ADR)
Ortho implants, CORI robotics, sports medicine — named rival in two segments.
- Boston Scientific
Vascular rival; Penumbra deal creates head-to-head contest with Inari in VTE.
- Globus Medical
Spine implants and ExcelsiusGPS robotics — #2 global spine rival to K2M.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Stryker | $334.18 | +1.06% | $126.77B | 34.3 | 20.6 | 4.9 | +9.4% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| Zimmer Biomet | $100.91 | −0.00% | $19.52B | 24.6 | 11.5 | 2.3 | +4.8% |
| Medtronic | $91.58 | +0.42% | $116.78B | 24.5 | 15.3 | 3.2 | +9.9% |
| Smith & Nephew (ADR) | $28.72 | −0.93% | $12.17B | 19.2 | — | 1.9 | +3.7% |
| Boston Scientific | $46.85 | +0.03% | $69.62B | 19.0 | 14.2 | 3.3 | +7.5% |
| Globus Medical | $85.02 | +2.47% | $11.19B | 21.3 | 16.2 | 3.6 | +5.9% |
| Median | 22.9 | 15.3 | 3.3 | +6.3% |